Dr Jay Charles Rudd, MD | |
345 College St Se, Suite C, Lacey, WA 98503-1013 | |
(360) 456-3200 | |
(360) 456-3894 |
Full Name | Dr Jay Charles Rudd |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Experience | 29 Years |
Location | 345 College St Se, Lacey, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699726687 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | MD00038444 (Washington) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Eye Physicians Of Olympia Inc Ps | 8123916962 | 13 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.
Doctors who provide pediatric care over the telephone - known as "telemedicine" - face a range of challenges that do not come with traditional face-to-face contact.
Children exposed to cigarette smoke have lower levels of antioxidants, which help the body defend itself against many biological stresses.
› Verified 1 days ago
Entity Name | Eye Physicians Of Olympia Inc Ps |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1821165911 PECOS PAC ID: 8123916962 Enrollment ID: O20040308000701 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.
Doctors who provide pediatric care over the telephone - known as "telemedicine" - face a range of challenges that do not come with traditional face-to-face contact.
Children exposed to cigarette smoke have lower levels of antioxidants, which help the body defend itself against many biological stresses.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Jay Charles Rudd, MD 3204 32nd Ct Nw, Olympia, WA 98502-3237 Ph: (360) 867-1844 | Dr Jay Charles Rudd, MD 345 College St Se, Suite C, Lacey, WA 98503-1013 Ph: (360) 456-3200 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.
Doctors who provide pediatric care over the telephone - known as "telemedicine" - face a range of challenges that do not come with traditional face-to-face contact.
Children exposed to cigarette smoke have lower levels of antioxidants, which help the body defend itself against many biological stresses.
› Verified 1 days ago
Dr. Stephen D Reck, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 College St Se, Suite C, Lacey, WA 98503 Phone: 360-456-3200 Fax: 360-456-3894 | |
Dr. Penporn Vongsvivut Reck, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 College St Se, Suite C, Lacey, WA 98503 Phone: 360-456-3200 Fax: 360-456-3894 | |
Dr. Gary Neal Scholes, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 345 College St Se, Suite C, Lacey, WA 98503 Phone: 360-456-3200 Fax: 360-456-3894 |